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HemolysisLegulcers (LUs) represent oneof themain causesofmorbidity in sickle cell anemia (SCA). Thismanifestation
has been related to hemolysis, infections predisposition and inﬂammation that leads cytokines secretion. In
this context, our study aimed to evaluate Th17 related cytokines (IL-6, IL-17A, IL-22 and IL-23) in serumand
peripheral mononuclear cells culture supernatants with and without lymphoproliferative stimulation
(anti-human CD3 and anti-human CD28). The cytokines levels were also correlated to clinical, hematolog-
ical and biochemical parameters in SCA patients with andwithout LUs history (SCALU and SCAWH) as well
as in healthy controls. In SCALU patients, high levels of IL-17Awere associated with absence of acute chest
syndrome (ACS, p = 0.0328). The other clinical parameters analyzed (osteonecrosis, stroke, priapism, sple-
nectomy and blood transfusions history)were not signiﬁcantly relatedwith other cytokine levels. In SCALU
patientswas alsoobserved that IL-17A increased levelswere associatedwithhigh levels of LDH(p = 0.0130),
the same association pattern was found for IL-6 (0.0160) and IL-22 (p = 0.0165) in the SCALU group. Inter-
estingly, we did not ﬁnd statistical correlationswith these parameters in SCAWHgroup. The other hemato-
logical parameters (hemoglobin, leucocyte and reticulocyte count) and indirect bilirrubin did not show any
correlation with analyzed cytokines in both groups. So, for the ﬁrst time, we show that IL-17A present in
SCALU patients may exert a preventive role in the ACS development. Furthermore, IL-6, IL-17A and IL-22
accompanied the LDH levels only in SCALU patients suggesting to serve as additional markers of hemolysis
or to be related with immunity response against extracellular pathogens.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
The leg ulcers (LUs) are a debilitating condition in sickle cell
anemia (SCA). This manifestation represents one of the most
important cases of morbidity in SCA patients [1]. The LUs usually
develops in SCA between 10 and 30 years old and with more pre-
valent in African countries [2]. These ulcers usually appear in the
ankle region and are characterized by slow healing, frequent local
pain and a high number of recurrences [3]. The pathophysiology of
LUs in SCA patients remains unclear. Mohan and coworkers argue
that the cause is due to venous insufﬁciency in the regions whereulcers develop, preventing normal blood ﬂow, causing hypoxia and
tissue infarction [4].
Acute chest syndrome (ACS), osteonecrosis, priapism and stroke
represent complications in SCA [5] being ACS the second most
common cause of hospitalization in SCA patients [6]. The ACS is
characterized by fever, leucocytosis, and respiratory symptoms
leading to chronic lung damages [7–9]. These clinical manifesta-
tions are involved in two main processes in sickle cell disease:
hemolysis and vascular occlusion [10]. Hemolysis leads to cardio-
vascular, pulmonary, gastrointestinal and renal manifestations
[11]. Besides that, leg ulcers were also related to the intensity of
hemolysis [12]. These events involve vascular occlusion and
inﬂammatory process that involve many cell types, inﬂammatory
mediators, cell adhesion molecules, and the presence of cytokines
and chemokines which recruit cells to inﬂammatory sites, and in-
duce immune responses [13–15].
IL-17A is the hallmark cytokine of Th17 cells and has been
shown to function as a proinﬂammatory cytokine that upregulates
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the recruitment of neutrophils into sites of inﬂammation [16]. IL-
22 is a family type II cytokine that is preferentially expressed by
differentiated Th17 cells [17] and thus considered as a Th17 cyto-
kine, but it is also expressed by other cells like CD8+ T cells and
CD11c+ dendritic cells as showed by Zheng and coworkers [18].
Overall, Th17 cells produce multiple effector cytokines with par-
tially overlapping roles in immunity. IL-23 can also directly pro-
mote Th17 differentiation by increasing RORct expression in
combination with IL-1 b and IL-6 [19]. IL-23 is a novel member
of the IL-12 cytokine family and it is composed by a unique p19
subunit and an identical p40 subunit to IL-12 whereas IL-12 drives
the classical Th1 response [20,21].
Most cytokine studies in SCA have evaluated cytokines pro-
duced by Th1 cells (IFN-c, IL-1, IL-2, IL-12) that are involved in in-
nate immunity [22–24] and produced by Th2 cells (IL-4, IL-5, IL-13)
in humoral immunity [25,26]. On the other hand, there are few
studies associating clinical proﬁles with other cytokines pathway
such as Th17 [27,28]. Th17 cells differentiation is driven by TGF-
b and IL-6 [29,30] and is reinforced by IL-23 [31,32]. These cells
mainly secrete IL-17 (A and F) but also produce IL-9 [33], IL-21,
IL-22, IL-26, and CCL20 [34].
These mediators are responsible for a number of effector func-
tions in host defense and in several autoimmune diseases [35].
Due to the lack of studies in this context, our study analyzed if
the cytokines IL-6, IL-17A, IL-22 and IL-23 were related to clinical
parameters in SCA patients with LUs. For this reason, we evaluated
hematological and biochemical markers to identify whether there
is a relation between the Th17 related cytokines and the laborato-
rial parameters in these patients.2. Materials and methods
2.1. Ethical approval
Ethics approval was obtained from ethical committee from
Health Science Center of Federal University of Pernambuco and
Hematology and Hemotherapy Foundation of Pernambuco (proto-
cols 483/10 and 57/10 respectively).
2.2. Patients
All SCA patient (HbSS) blood samples were obtained from Janu-
ary 2011 to June 2012 during regular clinical visits at the Hospital
of Hematology and Hemotherapy Foundation of Pernambuco
(HEMOPE), Brazil. The SCA patients were divided into two groups:
patients with active LUs (SCALU) and without LUs history
(SCAWH). Healthy individuals were used as controls and also col-
lected in the same place totalizing three groups. Informed written
consent and the clinical questionnaire were obtained from all pa-
tients and controls. The inclusion criteria for all patients were at
a steady-state condition and the exclusion criteria was to show
no other systemic diseases that could have potentially altered their
inﬂammatory proﬁle functions and did not receive transfusions in
less than 3 months or hydroxyurea therapy. All parameters used in
the study were conﬁrmed by clinical history contained in the med-
ical records of the institution.
2.3. Isolation and culture conditions for peripheral blood mononuclear
cells (PBMCs)
PBMCs were isolated from fresh peripheral blood collected in
sodium heparin tubes, following an adapted method described pre-
viously by English and Andersen [36]. Brieﬂy, whole blood was laid
over one layer of Ficoll–Paque Plus (density gradient of 1.077 g/L,GE Healtcare, Little Chalfont, UK) and centrifuged at 400g for
45 min, cells were washed once in PBS (pH 7.4) and washed once
more in PBS, RBC lysis buffer was used for contaminating red cells
for 10 min at 4 C (Ebioscience, San Diego, CA, USA). PBMCs were
incubated at 37 C for 48 h under two conditions: unstimulated
cells and stimulated cells with anti-human CD3 and anti-human
CD28 (anti-humanCD3 + anti-humanCD28, Ebioscience, San Diego,
CA, USA).
2.4. Cytokines measurements in serum and PBMCs culture
supernatants
Serum was obtained from blood samples that were collected
and centrifuged at 1258g for 15 min, and stored at 80 C. Com-
mercially available ELISA kits were used to determine IL-6 (BD Bio-
sciences, NJ, USA), IL-17A, IL-22 and IL-23 (Ebioscience, San Diego,
CA, USA). These cytokines were evaluated on culture supernatants
of PBMCs incubated during 48 h with or without stimulation with
anti-humanCD3 + anti-humanCD28 (Ebioscience, San Diego, CA,
USA). The ELISA plates were read at 450 nm and 570 nm (EL808,
Biotek, VT, USA). Following the detection limits of each kit: IL-6
(4.69 pg/ml), IL-17A (3.91 pg/ml), IL-22 (7.81 pg/ml), IL-23
(15.62 pg/ml).
2.5. Blood samples, hematological and biochemical evaluation
Peripheral blood samples obtained from EDTA tubes were ana-
lyzed for complete blood count (STKS, Coulter) and reticulocyte
count. Sera obtained tubes were used to analyze serum levels of
indirect bilirubin and lactate dehydrogenase (Cobas Integra plus
400, Roche).
2.6. Statistical analysis
Mann–Whitney test was used to correlate cytokines levels with
clinical parameters using Graphpad Prism software (Version 5.0).
The Spearman correlation test was used for hematological and bio-
chemical evaluation associated with cytokines levels using Origin
software (Version 8.0). A p value less than 0.05 was considered sta-
tistically signiﬁcant.
3. Results
3.1. Th17 related cytokines levels in serum and PBMCs culture
supernatants
First of all, we evaluated IL-6, IL-17A, IL-22 and IL-23 cytokines
levels in serum patients. Only a few SCALU and SCAWH patients
had cytokine levels above the kit’s detection limit (Supplementary
Fig. 1). All the three analyzed groups were not signiﬁcantly differ-
ent regarding their cytokine levels when comparing each other
(p > 0.05). Because of these results, the association of serum cyto-
kines levels with clinical, hematological and biochemical parame-
ters became unfeasible. In this sense, our analysis were focused
on PBMC culture supernatant. The IL-17A levels of stimulated cells
were signiﬁcantly higher in SCAWH group than controls (0.0195).
We also observed the IL-17A high levels in SCALU group compared
with controls but they were not signiﬁcant. The IL-6, IL-22 and IL-
23 levels was no statistical signiﬁcant in either group (Fig. 1).
3.2. Correlation between Th17 related cytokine levels with clinical
proﬁle
The levels of IL-6, IL-17A, IL-22 and IL-23 were correlated to:
acute chest syndrome, osteonecrosis, priapism, stroke, splenec-
Fig. 1. Levels of IL-6, IL-17A, IL-22 and IL-23 in PBMCs culture supernatants. Data presented are means () and + SEM (Standard Error Mean). *p value = 0.0195. SCALU
(n = 24), SCAWH (n = 38) and Control (n = 10).
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acterization of SCA patients (Table 1). Then we compared the pos-
sibility of associations within SCALU and SCAWH groups. In SCALU
patients high levels of IL17A were associated with absence of acute
chest syndrome (p = 0.0328). However IL-17A levels were also
more expressed in SCAWH than SCALU patients with ACS historic
(p = 0.0483). The associations of IL-17A with other parameters
were not signiﬁcant (Table 2). The ACS was conﬁrmed in all cases
by a new pulmonary inﬁltrate on Chester X-ray together with
SPO2. The IL-6, IL-22 and IL-23 levels were not signiﬁcantly associ-
ated with any clinical parameters (Supplementary Tables 1 and 2).3.3. Correlation between supernatant Th17 related cytokine levels with
laboratorial parameters
The Th17 related cytokines were correlated with value of Hb
(total hemoglobin), WBC (leukocyte count), Ret (reticulocyte
count), LDH (lactate dehydrogenase) and IB (indirect bilirrubin).
Only in SCALU patients was observed that increased levels of
LDH were positively correlated with IL-6 (p = 0.0191, r2 = 0.287),
IL-17A (p = 0.0130, r2 = 0.419) and IL-22 (r2 = 0.168) (Fig. 2). The
IL-23 had no positive correlation with any laboratorial parameter
(data not shown). These laboratorial markers are always signiﬁ-
cantly altered comparing sickle cell anemia patients with normal
controls.Table 1
Clinical parameters obtained from SCALU and SCAWH patients.
Clinical parameters SCALU (n = 24)
n (%Yes) n (%No)
Male/female 13/11
Age 35 (21–59)
Osteonecrosis 8 (33) 16 (67)
Acute chest syndrome 7 (21.2) 17 (71.8)
Priapisma 5 (4.1) 8 (95.9)
Stroke 1 (0.2) 23 (95.8)
Splenectomy 2 (8) 22 (92)
a The priapism percentage was considered only for men. The values represents numb4. Discussion
The classical view of sickle cell anemia has been focused on the
primary genetic defect that lead to hemoglobin polymerization
causing red cells deformity, becoming rigid, obstructing blood ﬂow,
and producing acute and chronic tissue damage because of poor
perfusion [37]. A more complete view that allows that the sticky,
stiff, oxidizing sickle red cell is an irritant process that not only ob-
struct blood ﬂow but also provokes an inﬂammatory response are
mandatory [38]. Serum markers of inﬂammation have provided
evidence for a state of chronic inﬂammation in SCA patients [39].
Inﬂammation promotes endothelial adherence to sickle erythro-
cytes, leukocytosis, in the absence of infection, common in SCA pa-
tients and predicts for stroke, acute chest syndrome, and overall
mortality [6].
Our results Th17 related cytokines correlation showed no dif-
ferences between detecting levels of IL-6, IL-17A IL-22 and IL23
in the serum of SCA patients and controls. In this latter case our re-
sult could be related with the nature appearing location of leg ul-
cers or the biological life time of these cytokines [40]. Levels of IL-
17A obtained from stimulated cells could point to new hypotheses
evaluation, mainly about the possible involvement of this cytokine
with SCA events [27]. We associated the Th17 related cytokine lev-
els in relation to the clinical history of each SCA group.
Vilas-Boas and coworkers [41] did not demonstrate correlation
of IL-4, IL-17, IL-23 and TGF-b with clinical events in SCA patientsSCAWH (n = 42) Control (n = 20)
n (%Yes) n (%No)
20/22 10/10
31 (18–50) 34 (21–58)
6 (14.2) 36 (85.8) –
18 (43) 24 (57) –
3 (17) 15 (83) –
3 (7.2) 39 (92.8) –
1 (12) 41 (98) –
er of patients (%) except Male/Female value are means (min–max).
Table 2
Levels of IL-17A associated with clinical parameters in SCALU and SCAWH patients.
Clinical parameters SCALU (n = 24) p Value SCAWH (n = 38) p Value SCALU X SCAWH
Yes No Yes No p Value
Acute chest syndrome 309.1 (124.5) 1956 (487.5) 0.0328 1156 (313.6) 1620 (464.3) 0.9650 0.0483
Osteonecrosis 1889 (697.4) 1226 (415.2) 0.5151 1292 (637.5) 1420 (320.3) 0.7793 0.9485
Priapism 1324 (430.1) 1840 (818.1) 0.9413 3981 (2349) 1240 (293.9) 0.3419 0.3929
Stroke 437.6 (0) 1491 (371.6) ND 1945 (950.6) 1353 (300.8) 0.2131 ND
Splenectomy 633.1 (629.2) 1276 (1433) ND 4374 (0) 1320 (280.7) ND ND
History of transfusions 1775 (800.3) 1104 (312.8) 0.3878 1619 (538.9) 1322 (339.8) 0.9868 1.000
Data presented as means (standard error). ND, Non-determined. The bold values indicate a statistical signiﬁcance (p < 0.05).
Fig. 2. Associated between of IL-6 (A), IL-17A (B) and IL-22 (C) Levels with lactate dehydrogenase values in SCALU patients.
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eters showed an interesting result. Only in SCALU patients, the in-
creased level of IL-17A was related with ACS. The ACS affects SCA
patients older than 2 years being considered one of the most fre-
quent complications and major cause of morbidity and mortality
in SCA [7]. Data from the Clinical Course of Sickle Cell Disease
Cooperative Study indicates that the ACS occurs in 10.5% of pa-
tients per year [8] where infectious agents are responsible for more
than one third of cases. Extensive antibiotic therapy is usually used
in this case, even when the infection does not have a clear etiology
[42]. IL-17 and IL-22 synergistically act to augment the expression
of genes involved in the defense against microbial pathogens such
as the b-defensin2 gene in keratinocytes [17]. For example, an
analysis of mycobacteria-speciﬁc Th17 cells in exposed humans re-
vealed that most of these cells expressed either IL-22 or IL-17 but
not both cytokines [43]. Consistent with this hypothesis, mice with
targeted deletion of IL-17RA have signiﬁcant defects in host de-
fense. IL-17R signaling is critical for G-CSF and CXC chemokine pro-
duction, and IL-17R deﬁcient mice exhibit a delay in neutrophil
recruitment into the alveolar space hindering the immune re-
sponse that would allow the destruction and expulsion of patho-
gens [44]. These data suggest that decreased levels of IL-17 could
favor the risk to infection. Our associations compared to clinical
parameters indicate that IL-17A may exert a preventive role in
the development of ACS related to pathogens. Because the results
were only found among patients with leg ulcers, possibly the ac-
tion of related Th17 cytokines is antimicrobial due to predisposing
factor of leg ulcers to local infections [45].
Taylor et al. hypothesized that the degree of hemolysis is a key
determinant inﬂuencing a phenomic spectrum of complications
that reﬂect the severity of sickle vasculopathy. In sickle cell disease
two thirds of hemolysis occur extravascularly, the remaining one
third of red cells hemolyzeintravascularly. Along with reticulocyte
count, indirect bilirubin level, and serum haptoglobin, LDH has
been used as a marker of hemolysis. Serum LDH is also usually ele-
vated in sickle cell anemia in the steady state. This robust hemo-
lytic rate increases even more during vaso-occlusive pain crisis
(VOC) [46]. Our results reveal that the LDH levels positively corre-
lated with IL-6, IL-17A and IL-22 being favorable for hemolysis.This hemolysis will lead to ischemic events involving interactions
between erythrocytes, leukocytes and endothelium cells [15].
Although the levels of hemoglobin, reticulocytes, leukocytes and
bilirubin are abnormal when compared to healthy controls, our re-
sults indicated that there was no positive correlation related to IL-
17A and IL-22 levels.
It is possible to deﬁne the presence of pathogens is strongly re-
lated to the formation of bioﬁlms. This colonization of bacteria pre-
dominantly characterize chronic wounds, with the presence of
inﬂammatory exudate, poor healing and chronic ulcers, present
in the group with sickle cell leg ulcers [47,48]. Due to the presence
of cytokines related to Th17 only in SCALU patients, there may be
an association between these cytokines and the role of immunity
against extracellular pathogens in these patients. Thus our data to-
gether shows that IL-17A and IL-22 cytokines act as biomarkers of
clinical and hematological changes in patients with ACS points out
some differences between SCALU and SCAWH patients that could
be correlated with different clinical and biological behavior of
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